In January 2023, Senator Breslin and Assemblyman McDonald reintroduced four step-therapy bills that would create additional protections for patients in New York. The bills include:
– S.2682/A.582: Prohibits the applicability of step therapy policies to certain therapeutic categories, including dermatology, gastroenterology, hematology, neurology, oncology, ophthalmology, and rheumatology
– S.2800/A.1384: Requires insurers and utilization review agents to report certain information regarding step-therapy override requests, including the number of step-therapy override requests, approvals, and reversals
– S.2677/A.463: Requires plans to provide adequate notice of adverse step-therapy determinations, including the reason for the determination instructions to appeal
– S.1267/A.901: Requires plans and utilization review agents to follow certain rules when establishing a step therapy protocol, including prohibiting requiring patients to step through an off-label medication or trying and failing on more than one drug
– On January 17, 2023, the bill passed the Senate and was delivered to the Assembly.
Learn more about each bill in our fact sheet.
Last Updated on February 3, 2023 by Aimed Alliance
